Julius Clinical

Major Milestone Achieved in GRIPonMASH! We’re excited to announce that all sites across 10 European countries are now active in the GRIPonMASH study! This marks a significant step toward our goal of continuing to screen 10,000 high-risk patients for liver steatosis and liver fibrosis (MASLD/MASH).   With this milestone, our focus now shifts to ensuring high-quality data collection and the safe delivery of thousands of samples to the biobank—critical steps in advancing research and improving patient outcomes.   A huge thank you to everyone involved for making this possible! 👏 Your dedication and teamwork are driving real progress in the fight against liver disease. See how you can support innovation in liver health: https://lnkd.in/etM-rnev

Just 1 week to go until the American Epilepsy Society AES Annual Meeting 2025 in Atlanta! Our colleagues Rob Kingston, Alyssa Pogue, Barbara Etter , and Steve Asche will represent Julius Clinical — proud sponsors of this year’s event — as we join peers from across the neuroscience community to discuss innovation in epilepsy research and clinical development. We look forward to meeting you at Booth #830 and exploring new ways to accelerate progress in neurology trials. Or contact us after the event: https://lnkd.in/enKtKq7G

One week after announcing our merger with P95, we remain energized by our shared mission and the possibilities ahead. As Bassem Saleh, M.D., CEO of the combined organization, shared: “I am honored to lead these two organizations forward together—delivering unmatched, science-led research across the full development lifecycle and supporting innovation that improves lives worldwide.” Together, we’re creating a global, science-led CRO with the scale to deliver and the agility to care—advancing science and improving health worldwide. Led by CEO Bassem Saleh, with founder Thomas Verstraeten continuing as Board Member and Senior Advisor, we’re creating a global, science-led CRO with the scale to deliver and the agility to care—advancing science and improving health worldwide. Learn more in the full press release: https://lnkd.in/eFQBpN9T #JuliusClinical #P95 #CRO #ClinicalTrials #GlobalHealth #Neuroscience #CardioRenalMetabolic #RealWorldEvidence #AdvancingHealth

Julius Clinical is growing! We’re excited to announce two new opportunities to join our team: 📍 Market Strategy Manager (Inside Sales) – Barcelona https://lnkd.in/emb_Pu4A 📍 Clinical Research Associate – Netherlands https://lnkd.in/dBSRR7zk Are you passionate about driving market strategies or advancing clinical trials to make a real-world impact in healthcare? Apply now and become part of our science-driven, collaborative environment:

Ampersand Capital Partners portfolio companies P95 and Julius Clinical have officially merged, forming a global, science-led CRO with more than 500 experts across 25+ countries. Led by CEO Bassem Saleh, with founder Thomas Verstraeten continuing as Board Member and Senior Advisor, this new organization is uniquely positioned to advance high-quality, science-driven research that improves health worldwide. A huge milestone and an exciting new chapter for both teams! https://lnkd.in/eXvAXSpe

We’re excited to share important news from Julius Clinical. Today, Julius Clinical and P95 have merged to form a global mid-sized, full-service contract research organization (CRO)—uniting complementary strengths in clinical development and real-world evidence. By combining Julius Clinical’s leadership in neuroscience and cardio-renal-metabolic clinical research with P95’s expertise in infectious diseases, vaccines, and real-world evidence, we’re creating a science-led organization with the scale to deliver and the agility to care. Together, we’ll continue to deliver high-quality, science-led research—guided by shared values, deep scientific leadership, and a commitment to advancing patient care worldwide. Led by CEO Bassem Saleh, with founder Thomas Verstraeten continuing as Board Member and Senior Advisor, this new organization is uniquely positioned to advance high-quality, science-driven research that improves health worldwide. A huge milestone and an exciting new chapter for both teams! Read the full press release: https://lnkd.in/eFQBpN9T #JuliusClinical #ClinicalTrials #Neuroscience #CardioRenalMetabolic #CRO #GlobalResearch #P95 #Merger #AdvancingHealth

Julius Clinical at the ACDM RBQM Symposium 2025 Next week, Gyorgyi Kiss and Lotte Smets will represent Julius Clinical at the ACDM: Association for Clinical Data Management RBQM Symposium in Amsterdam 🇳🇱 on November 10–11, 2025. This key event brings together industry leaders to explore Risk-Based Quality Management (RBQM) and its impact on clinical trials, data integrity, and operational excellence. We’re proud to be part of these important conversations shaping the future of clinical research. At Julius Clinical, we help sponsors implement RBQM strategies that ensure compliance, optimize monitoring, and enhance overall trial quality. If you’re attending and want to learn how we can support your RBQM initiatives, let’s connect during the event or reach out to us directly! Contact us: https://lnkd.in/enKtKq7G

We’ve officially opened the doors to our new office, and marked the occasion with a special soft opening led by our CEO, Bassem Saleh, complete with a ribbon-cutting moment to celebrate this exciting milestone. This new space reflects our continued growth and commitment to advancing clinical research through collaboration, innovation, and excellence. We’re looking forward to all that’s ahead and to welcoming our teams and partners into this inspiring environment. You can find our new address here: https://lnkd.in/enKtKq7G

Julius Clinical is at CNS Summit 2025 in Boston! Rob Kingston, Alyssa Pogue and Steve Asche will be on site representing Julius Clinical, joining global leaders to discuss the latest innovations shaping neuroscience and clinical development. We’re excited to connect with peers, partners, and innovators driving progress in CNS research. 👉 If you’re attending, reach out and let’s explore how Julius Clinical can support your next CNS trial.

Cardiovascular disease is Europe’s leading cause of death. Yet one highly prevalent condition remains largely unaddressed in prevention guidelines: Metabolic dysfunction-associated steatotic liver disease (MASLD). Including MASLD in cardiovascular strategies will improve early detection, risk assessment, and long-term outcomes. Read the latest paper put out by Manuel Castro Cabezas, Diederick (Rick) E. Grobbee, MD, PhD, FESC and GRIPonMASH colleagues in collaboration with European Liver Patients' Association - ELPA. Reach out to Manuel Castro Cabezas to learn how we can support your study.